Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 6/2012

01.06.2012 | Reply

Reply

verfasst von: S. M. Hadi

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Excerpt

The article by Ullah et al. [1] published by us followed from the paper of Levine and co-workers [2], wherein these authors had expressed their inability to explain the molecular basis for the relative resistance of normal cells to the cytotoxic action of ascorbic acid. Our results are actually in support of the results of Levine and his group. However, they are an attempt to explain one of the aspects of the results of these authors. Therefore, as mentioned in the letter submitted by Rodemeister et al., the question of not supporting the results of Chen et al. [2] does not arise. Although we realize that we have not used tumor cells in our study, such work has already been done by Levine and his group and many other workers as mentioned in our paper. In the discussion of our paper, we say that based on our results with normal cells and the results of various other groups, it is our ‘belief’ that the preferential cytotoxic action of ascorbic acid against cancer cells is explained by the ability of ascorbic acid to mobilize endogenous copper ions. In support of our idea, we have also given several lines of indirect evidence in literature. …
Literatur
1.
Zurück zum Zitat Ullah MF, Khan HY, Zubair H, Shamim U, Hadi SM (2011) The antioxidant ascorbic acid mobilizes nuclear copper leading to a prooxidant breakage of cellular DNA: implications for chemotherapeutic action against cancer. Cancer Chemother Pharmacol 67:103–110PubMedCrossRef Ullah MF, Khan HY, Zubair H, Shamim U, Hadi SM (2011) The antioxidant ascorbic acid mobilizes nuclear copper leading to a prooxidant breakage of cellular DNA: implications for chemotherapeutic action against cancer. Cancer Chemother Pharmacol 67:103–110PubMedCrossRef
2.
Zurück zum Zitat Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, Krishna MC, Khosh DB, Drisko J, Levine M (2008) Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci USA 105:11105–11109PubMedCrossRef Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, Krishna MC, Khosh DB, Drisko J, Levine M (2008) Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci USA 105:11105–11109PubMedCrossRef
3.
Zurück zum Zitat Wilms LC, Claughton TA, de Kok TM, Kleinjans JC (2007) GSTM1 and GSTT1 polymorphism influences protection against induced oxidative DNA damage by quercetin and ascorbic acid in human lymphocytes in vitro. Food Chem Toxicol 45:2592–2596PubMedCrossRef Wilms LC, Claughton TA, de Kok TM, Kleinjans JC (2007) GSTM1 and GSTT1 polymorphism influences protection against induced oxidative DNA damage by quercetin and ascorbic acid in human lymphocytes in vitro. Food Chem Toxicol 45:2592–2596PubMedCrossRef
Metadaten
Titel
Reply
verfasst von
S. M. Hadi
Publikationsdatum
01.06.2012
Verlag
Springer-Verlag
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 6/2012
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-012-1861-7

Weitere Artikel der Ausgabe 6/2012

Cancer Chemotherapy and Pharmacology 6/2012 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.